Screening and mechanistic study of natural compounds that enhance T cell anti-tumor effects post-heat treatment
Following the approval of Chimeric Antigen Receptor T-cell Immunotherapy(CAR-T) in multiple countries, the Food and Drug Administration (FDA) approved tumor-infiltrating lymphocytes (TILs) and T-cell receptor-engineered T cells (TCR-T) treatments this year. The utilization of adoptive immunotherapy...
Saved in:
Published in | Frontiers in immunology Vol. 16; p. 1537398 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
27.03.2025
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Following the approval of Chimeric Antigen Receptor T-cell Immunotherapy(CAR-T) in multiple countries, the Food and Drug Administration (FDA) approved tumor-infiltrating lymphocytes (TILs) and T-cell receptor-engineered T cells (TCR-T) treatments this year. The utilization of adoptive immunotherapy in tumor treatment has become increasingly prominent. Optimizing the cytotoxic effects of immune cells under
culture conditions represents a current hot research topic in this domain.
In the current experiment, we conducted
heat treatment on Jurkat-derived T cells at 39°C. On this basis, we utilized nine distinct injectable solutions and over 70 monomer components of Traditional Chinese Medicine (TCM). Subsequently, we co-cultured these treated Jurkat cells with K562-eGFP cells, and the co-culture process was monitored in real-time using the IncuCyte live-cell analysis system. Equally important, we combined HiMAP high-throughput transcriptome sequencing, proteomics, and metabolomics for in-depth examination. We screened for compounds possessing anti-tumor properties and thoroughly investigated their mechanisms of action.
The findings indicated that heating treatment augmented the cytotoxic effect of Jurkat cells against malignant tumors, and the optimal effect was achieved when T cells were exposed to 39°C for a duration of 24 hours(48% increase in cell proliferation rate compared to 37°C treatment). By triggering the generation of heat shock proteins and facilitating mitochondrial energy supply, the 39°C treatment amplified the anti-tumor functions of T cells. By analyzing the data, we identified 3 injectable solutions and more than 20 effective monomers capable of further enhancing the tumor-killing ability of T cells. High-throughput transcriptomics studies disclosed that the combination of thermotherapy and TCM promoted Jurkat cell proliferation, activation, and cytotoxic functions of Jurkat cells, thereby activating the Regulation of mitotic cell cycle to exert anti-tumor effects. The integration of transcriptomic and proteomic data demonstrated that Shengmai Injection significantly enhances the tumor-killing effect of Jurkat cells by down-regulating the Regulation of Apoptosis and Regulation of mitotic cell cycle signaling pathways. |
---|---|
AbstractList | IntroductionFollowing the approval of Chimeric Antigen Receptor T-cell Immunotherapy(CAR-T) in multiple countries, the Food and Drug Administration (FDA) approved tumor-infiltrating lymphocytes (TILs) and T-cell receptor-engineered T cells (TCR-T) treatments this year. The utilization of adoptive immunotherapy in tumor treatment has become increasingly prominent. Optimizing the cytotoxic effects of immune cells under in vitro culture conditions represents a current hot research topic in this domain.MethodsIn the current experiment, we conducted in vitro heat treatment on Jurkat-derived T cells at 39°C. On this basis, we utilized nine distinct injectable solutions and over 70 monomer components of Traditional Chinese Medicine (TCM). Subsequently, we co-cultured these treated Jurkat cells with K562-eGFP cells, and the co-culture process was monitored in real-time using the IncuCyte live-cell analysis system. Equally important, we combined HiMAP high-throughput transcriptome sequencing, proteomics, and metabolomics for in-depth examination. We screened for compounds possessing anti-tumor properties and thoroughly investigated their mechanisms of action.Results and DiscussionThe findings indicated that heating treatment augmented the cytotoxic effect of Jurkat cells against malignant tumors, and the optimal effect was achieved when T cells were exposed to 39°C for a duration of 24 hours(48% increase in cell proliferation rate compared to 37°C treatment). By triggering the generation of heat shock proteins and facilitating mitochondrial energy supply, the 39°C treatment amplified the anti-tumor functions of T cells. By analyzing the data, we identified 3 injectable solutions and more than 20 effective monomers capable of further enhancing the tumor-killing ability of T cells. High-throughput transcriptomics studies disclosed that the combination of thermotherapy and TCM promoted Jurkat cell proliferation, activation, and cytotoxic functions of Jurkat cells, thereby activating the Regulation of mitotic cell cycle to exert anti-tumor effects. The integration of transcriptomic and proteomic data demonstrated that Shengmai Injection significantly enhances the tumor-killing effect of Jurkat cells by down-regulating the Regulation of Apoptosis and Regulation of mitotic cell cycle signaling pathways. Following the approval of Chimeric Antigen Receptor T-cell Immunotherapy(CAR-T) in multiple countries, the Food and Drug Administration (FDA) approved tumor-infiltrating lymphocytes (TILs) and T-cell receptor-engineered T cells (TCR-T) treatments this year. The utilization of adoptive immunotherapy in tumor treatment has become increasingly prominent. Optimizing the cytotoxic effects of immune cells under culture conditions represents a current hot research topic in this domain. In the current experiment, we conducted heat treatment on Jurkat-derived T cells at 39°C. On this basis, we utilized nine distinct injectable solutions and over 70 monomer components of Traditional Chinese Medicine (TCM). Subsequently, we co-cultured these treated Jurkat cells with K562-eGFP cells, and the co-culture process was monitored in real-time using the IncuCyte live-cell analysis system. Equally important, we combined HiMAP high-throughput transcriptome sequencing, proteomics, and metabolomics for in-depth examination. We screened for compounds possessing anti-tumor properties and thoroughly investigated their mechanisms of action. The findings indicated that heating treatment augmented the cytotoxic effect of Jurkat cells against malignant tumors, and the optimal effect was achieved when T cells were exposed to 39°C for a duration of 24 hours(48% increase in cell proliferation rate compared to 37°C treatment). By triggering the generation of heat shock proteins and facilitating mitochondrial energy supply, the 39°C treatment amplified the anti-tumor functions of T cells. By analyzing the data, we identified 3 injectable solutions and more than 20 effective monomers capable of further enhancing the tumor-killing ability of T cells. High-throughput transcriptomics studies disclosed that the combination of thermotherapy and TCM promoted Jurkat cell proliferation, activation, and cytotoxic functions of Jurkat cells, thereby activating the Regulation of mitotic cell cycle to exert anti-tumor effects. The integration of transcriptomic and proteomic data demonstrated that Shengmai Injection significantly enhances the tumor-killing effect of Jurkat cells by down-regulating the Regulation of Apoptosis and Regulation of mitotic cell cycle signaling pathways. Following the approval of Chimeric Antigen Receptor T-cell Immunotherapy(CAR-T) in multiple countries, the Food and Drug Administration (FDA) approved tumor-infiltrating lymphocytes (TILs) and T-cell receptor-engineered T cells (TCR-T) treatments this year. The utilization of adoptive immunotherapy in tumor treatment has become increasingly prominent. Optimizing the cytotoxic effects of immune cells under in vitro culture conditions represents a current hot research topic in this domain.IntroductionFollowing the approval of Chimeric Antigen Receptor T-cell Immunotherapy(CAR-T) in multiple countries, the Food and Drug Administration (FDA) approved tumor-infiltrating lymphocytes (TILs) and T-cell receptor-engineered T cells (TCR-T) treatments this year. The utilization of adoptive immunotherapy in tumor treatment has become increasingly prominent. Optimizing the cytotoxic effects of immune cells under in vitro culture conditions represents a current hot research topic in this domain.In the current experiment, we conducted in vitro heat treatment on Jurkat-derived T cells at 39°C. On this basis, we utilized nine distinct injectable solutions and over 70 monomer components of Traditional Chinese Medicine (TCM). Subsequently, we co-cultured these treated Jurkat cells with K562-eGFP cells, and the co-culture process was monitored in real-time using the IncuCyte live-cell analysis system. Equally important, we combined HiMAP high-throughput transcriptome sequencing, proteomics, and metabolomics for in-depth examination. We screened for compounds possessing anti-tumor properties and thoroughly investigated their mechanisms of action.MethodsIn the current experiment, we conducted in vitro heat treatment on Jurkat-derived T cells at 39°C. On this basis, we utilized nine distinct injectable solutions and over 70 monomer components of Traditional Chinese Medicine (TCM). Subsequently, we co-cultured these treated Jurkat cells with K562-eGFP cells, and the co-culture process was monitored in real-time using the IncuCyte live-cell analysis system. Equally important, we combined HiMAP high-throughput transcriptome sequencing, proteomics, and metabolomics for in-depth examination. We screened for compounds possessing anti-tumor properties and thoroughly investigated their mechanisms of action.The findings indicated that heating treatment augmented the cytotoxic effect of Jurkat cells against malignant tumors, and the optimal effect was achieved when T cells were exposed to 39°C for a duration of 24 hours(48% increase in cell proliferation rate compared to 37°C treatment). By triggering the generation of heat shock proteins and facilitating mitochondrial energy supply, the 39°C treatment amplified the anti-tumor functions of T cells. By analyzing the data, we identified 3 injectable solutions and more than 20 effective monomers capable of further enhancing the tumor-killing ability of T cells. High-throughput transcriptomics studies disclosed that the combination of thermotherapy and TCM promoted Jurkat cell proliferation, activation, and cytotoxic functions of Jurkat cells, thereby activating the Regulation of mitotic cell cycle to exert anti-tumor effects. The integration of transcriptomic and proteomic data demonstrated that Shengmai Injection significantly enhances the tumor-killing effect of Jurkat cells by down-regulating the Regulation of Apoptosis and Regulation of mitotic cell cycle signaling pathways.Results and DiscussionThe findings indicated that heating treatment augmented the cytotoxic effect of Jurkat cells against malignant tumors, and the optimal effect was achieved when T cells were exposed to 39°C for a duration of 24 hours(48% increase in cell proliferation rate compared to 37°C treatment). By triggering the generation of heat shock proteins and facilitating mitochondrial energy supply, the 39°C treatment amplified the anti-tumor functions of T cells. By analyzing the data, we identified 3 injectable solutions and more than 20 effective monomers capable of further enhancing the tumor-killing ability of T cells. High-throughput transcriptomics studies disclosed that the combination of thermotherapy and TCM promoted Jurkat cell proliferation, activation, and cytotoxic functions of Jurkat cells, thereby activating the Regulation of mitotic cell cycle to exert anti-tumor effects. The integration of transcriptomic and proteomic data demonstrated that Shengmai Injection significantly enhances the tumor-killing effect of Jurkat cells by down-regulating the Regulation of Apoptosis and Regulation of mitotic cell cycle signaling pathways. |
Author | Diao, Zhongqi Zhang, Yiyan Yang, Siyun Li, Yeshan Wang, Haojia Liu, Jiangying Wang, Tieshan Wang, Zhaoyi Zhen, Huimin Sun, Zijin Ni, Lei |
AuthorAffiliation | 3 School of Life Sciences, Beijing University of Chinese Medicine , Beijing , China 5 Beijing Research Institute of Chinese Medicine, Beijing University of Chinese Medicine , Beijing , China 4 School of Chinese Materia Medica, Beijing University of Chinese Medicine , Beijing , China 2 Department of Cancer Research Institute, Affiliated Cancer Hospital of Xinjiang Medical University , Urumqi , China 1 School of Traditional Chinese Medicine, Beijing University of Chinese Medicine , Beijing , China |
AuthorAffiliation_xml | – name: 3 School of Life Sciences, Beijing University of Chinese Medicine , Beijing , China – name: 4 School of Chinese Materia Medica, Beijing University of Chinese Medicine , Beijing , China – name: 1 School of Traditional Chinese Medicine, Beijing University of Chinese Medicine , Beijing , China – name: 2 Department of Cancer Research Institute, Affiliated Cancer Hospital of Xinjiang Medical University , Urumqi , China – name: 5 Beijing Research Institute of Chinese Medicine, Beijing University of Chinese Medicine , Beijing , China |
Author_xml | – sequence: 1 givenname: Zhaoyi surname: Wang fullname: Wang, Zhaoyi – sequence: 2 givenname: Zhongqi surname: Diao fullname: Diao, Zhongqi – sequence: 3 givenname: Yiyan surname: Zhang fullname: Zhang, Yiyan – sequence: 4 givenname: Jiangying surname: Liu fullname: Liu, Jiangying – sequence: 5 givenname: Yeshan surname: Li fullname: Li, Yeshan – sequence: 6 givenname: Zijin surname: Sun fullname: Sun, Zijin – sequence: 7 givenname: Huimin surname: Zhen fullname: Zhen, Huimin – sequence: 8 givenname: Haojia surname: Wang fullname: Wang, Haojia – sequence: 9 givenname: Siyun surname: Yang fullname: Yang, Siyun – sequence: 10 givenname: Tieshan surname: Wang fullname: Wang, Tieshan – sequence: 11 givenname: Lei surname: Ni fullname: Ni, Lei |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40213558$$D View this record in MEDLINE/PubMed |
BookMark | eNpVUk1vGyEQRVWiJnXzB3qoOPayLp_r3VNVRc2HFKmHJmeEh8HeaBdcYCvl3xfHTpRwgBG8eW9meJ_ISYgBCfnC2VLKrv_uh2mal4IJveRarmTffSDnvG1VI4VQJ2_iM3KR8yOrS_VSSv2RnCkmuNS6OyfxDyTEMIQNtcHRCWFrw5DLADSX2T3R6GmwZU52pBCnXZyDy7RsbaEYKhSQ3lPAcazpZWjKPMVE0XuEkuku5tJssWJLqvuEoXwmp96OGS-O54I8XP26v7xp7n5f317-vGtACVEap70A51uUoheM-zUAt0LorkcHrIUVR66tsqAYOKm070F0UgtnkXdOtnJBbg-8LtpHs0vDZNOTiXYwzxcxbYxNtcsRjbA1qV_rVYsrpbC3Wlu2bluvgINGqFw_Dly7eT1V_dpGHcc70vcvYdiaTfxnOO9rUXpfzbcjQ4p_Z8zFTEPeT80GjHM2knddJxir8AX5-lbsVeXlyypAHACQYs4J_SuEM7O3hnm2htlbwxytIf8DJwWvtQ |
Cites_doi | 10.1002/ptr.v38.11 10.1186/s12943-019-1102-3 10.1038/s41408-024-01195-4 10.1186/s40364-022-00434-9 10.1038/nri3843 10.1016/j.biopha.2019.109570 10.1126/sciimmunol.adp3475 10.1016/j.smim.2015.11.003 10.1016/j.ebiom.2022.103941 10.1007/s12185-020-02827-8 10.1016/j.biopha.2023.114870 10.1038/s41577-024-01101-w 10.1016/j.biopha.2017.10.043 10.1016/j.ymthe.2020.09.015 10.1142/S0192415X20500780 10.3389/fimmu.2024.1352805 10.1146/annurev-med-062315-120245 10.3390/nu10010091 10.3389/fimmu.2020.00176 10.1073/pnas.2023752118 10.3389/fimmu.2023.1101495 10.3390/ijms19071970 10.1038/s41423-020-0488-6 10.1016/j.canlet.2019.07.017 |
ContentType | Journal Article |
Copyright | Copyright © 2025 Wang, Diao, Zhang, Liu, Li, Sun, Zhen, Wang, Yang, Wang and Ni. Copyright © 2025 Wang, Diao, Zhang, Liu, Li, Sun, Zhen, Wang, Yang, Wang and Ni 2025 Wang, Diao, Zhang, Liu, Li, Sun, Zhen, Wang, Yang, Wang and Ni |
Copyright_xml | – notice: Copyright © 2025 Wang, Diao, Zhang, Liu, Li, Sun, Zhen, Wang, Yang, Wang and Ni. – notice: Copyright © 2025 Wang, Diao, Zhang, Liu, Li, Sun, Zhen, Wang, Yang, Wang and Ni 2025 Wang, Diao, Zhang, Liu, Li, Sun, Zhen, Wang, Yang, Wang and Ni |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
DOI | 10.3389/fimmu.2025.1537398 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ (Directory of Open Access Journals) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1664-3224 |
ExternalDocumentID | oai_doaj_org_article_2aae19b576e744e9a55a0b66f4c1c5ec PMC11983556 40213558 10_3389_fimmu_2025_1537398 |
Genre | Journal Article |
GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EBS EMOBN GROUPED_DOAJ GX1 HYE KQ8 M~E OK1 PGMZT RNS RPM CGR CUY CVF ECM EIF IPNFZ M48 NPM RIG 7X8 5PM |
ID | FETCH-LOGICAL-c422t-d5f2cdf6e329201fbcc1a22589edc06c71e15a4ac40cd345f9c28352dae18d363 |
IEDL.DBID | DOA |
ISSN | 1664-3224 |
IngestDate | Wed Aug 27 01:25:33 EDT 2025 Thu Aug 21 18:27:58 EDT 2025 Fri Apr 11 19:19:18 EDT 2025 Sun Apr 13 01:31:26 EDT 2025 Tue Jul 01 05:14:38 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Chinese medicine untargeted metabolomics proteomics RNA-Seq enhance immunity temperature adoptive cell therapy |
Language | English |
License | Copyright © 2025 Wang, Diao, Zhang, Liu, Li, Sun, Zhen, Wang, Yang, Wang and Ni. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c422t-d5f2cdf6e329201fbcc1a22589edc06c71e15a4ac40cd345f9c28352dae18d363 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Reviewed by: Jiawei Ling, Zhejiang University, China Wenshe Sun, Qingdao University, China Zhenzhen Yang, Peking University Third Hospital, China Shang Zhihao, Nanjing University of Chinese Medicine, China Edited by: Valentyn Oksenych, University of Bergen, Norway |
OpenAccessLink | https://doaj.org/article/2aae19b576e744e9a55a0b66f4c1c5ec |
PMID | 40213558 |
PQID | 3188820098 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_2aae19b576e744e9a55a0b66f4c1c5ec pubmedcentral_primary_oai_pubmedcentral_nih_gov_11983556 proquest_miscellaneous_3188820098 pubmed_primary_40213558 crossref_primary_10_3389_fimmu_2025_1537398 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2025-03-27 |
PublicationDateYYYYMMDD | 2025-03-27 |
PublicationDate_xml | – month: 03 year: 2025 text: 2025-03-27 day: 27 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland |
PublicationTitle | Frontiers in immunology |
PublicationTitleAlternate | Front Immunol |
PublicationYear | 2025 |
Publisher | Frontiers Media S.A |
Publisher_xml | – name: Frontiers Media S.A |
References | Beavis (B3) 2016; 28 Jiang (B4) 2019; 462 Zhang (B24) 2018; 19 Tang (B22) 2024; 38 Albarrán (B6) 2024; 15 Wang (B19) 2020; 121 Gumber (B12) 2022; 77 Evans (B15) 2015; 15 Liu (B13) 2022; 10 Lee (B23) 2018; 10 Zhang (B2) 2020; 17 Hosen (B8) 2020; 111 Wang (B5) 2020; 11 Newick (B10) 2017; 68 Jiang (B21) 2017; 96 Wang (B18) 2020; 48 Zhang (B9) 2023; 14 Wagner (B11) 2020; 28 Epperla (B7) 2024; 14 Bird (B14) 2024; 24 Heintzman (B17) 2024; 9 Lu (B20) 2023; 163 Li (B1) 2019; 18 O’Sullivan (B16) 2021; 118 |
References_xml | – volume: 38 year: 2024 ident: B22 article-title: Ginsenoside Re inhibits non-small cell lung cancer progression by suppressing macrophage M2 polarization induced by AMPKα1/STING positive feedback loop publication-title: Phytother Res doi: 10.1002/ptr.v38.11 – volume: 18 start-page: 16 year: 2019 ident: B1 article-title: Harnessing tumor-associated macrophages as aids for cancer immunotherapy publication-title: Mol Cancer doi: 10.1186/s12943-019-1102-3 – volume: 14 start-page: 210 year: 2024 ident: B7 article-title: Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma publication-title: Blood Cancer J doi: 10.1038/s41408-024-01195-4 – volume: 10 start-page: 86 year: 2022 ident: B13 article-title: Strategies to enhance CAR-T persistence publication-title: biomark Res doi: 10.1186/s40364-022-00434-9 – volume: 15 year: 2015 ident: B15 article-title: Fever and the thermal regulation of immunity: the immune system feels the heat publication-title: Nat Rev Immunol doi: 10.1038/nri3843 – volume: 121 start-page: 9 year: 2020 ident: B19 article-title: Antitumor effects of immunity-enhancing traditional Chinese medicine publication-title: BioMed Pharmacother doi: 10.1016/j.biopha.2019.109570 – volume: 9 year: 2024 ident: B17 article-title: Subset-specific mitochondrial stress and DNA damage shape T cell responses to fever and inflammation publication-title: Sci Immunol doi: 10.1126/sciimmunol.adp3475 – volume: 28 start-page: 64 year: 2016 ident: B3 article-title: Reprogramming the tumor microenvironment to enhance adoptive cellular therapy publication-title: Semin Immunol doi: 10.1016/j.smim.2015.11.003 – volume: 77 start-page: 103941 year: 2022 ident: B12 article-title: Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion publication-title: EBioMedicine doi: 10.1016/j.ebiom.2022.103941 – volume: 111 year: 2020 ident: B8 article-title: Chimeric antigen receptor T-cell therapy for multiple myeloma publication-title: Int J Hematol doi: 10.1007/s12185-020-02827-8 – volume: 163 start-page: 11 year: 2023 ident: B20 article-title: Ginsenoside Rb1 stabilized and paclitaxel/protopanaxadiol co-loaded nanoparticles for synergistic treatment of breast tumor publication-title: BioMed Pharmacother doi: 10.1016/j.biopha.2023.114870 – volume: 24 year: 2024 ident: B14 article-title: Fever affects T cell fate publication-title: Nat Rev Immunol doi: 10.1038/s41577-024-01101-w – volume: 96 year: 2017 ident: B21 article-title: Ginsenoside Rg3 enhances the anti- proliferative activity of erlotinib in pancreatic cancer cell lines by downregulation of EGFR/PI3K/Akt signaling pathway publication-title: BioMed Pharmacother doi: 10.1016/j.biopha.2017.10.043 – volume: 28 year: 2020 ident: B11 article-title: CAR T cell therapy for solid tumors: bright future or dark reality publication-title: Mol Ther doi: 10.1016/j.ymthe.2020.09.015 – volume: 48 year: 2020 ident: B18 article-title: Positive role of chinese herbal medicine in cancer immune regulation publication-title: Am J Chin Med doi: 10.1142/S0192415X20500780 – volume: 15 year: 2024 ident: B6 article-title: Adoptive T cell therapy for solid tumors: current landscape and future challenges publication-title: Front Immunol doi: 10.3389/fimmu.2024.1352805 – volume: 68 year: 2017 ident: B10 article-title: CAR T cell therapy for solid tumors publication-title: Annu Rev Med doi: 10.1146/annurev-med-062315-120245 – volume: 10 start-page: 15 year: 2018 ident: B23 article-title: Deoxyschizandrin, isolated from schisandra berries, induces cell cycle arrest in ovarian cancer cells and inhibits the protumoural activation of tumour-associated macrophages publication-title: Nutrients doi: 10.3390/nu10010091 – volume: 11 year: 2020 ident: B5 article-title: Adoptive cell therapy targeting neoantigens: A frontier for cancer research publication-title: Front Immunol doi: 10.3389/fimmu.2020.00176 – volume: 118 year: 2021 ident: B16 article-title: Fever supports CD8(+) effector T cell responses by promoting mitochondrial translation publication-title: Proc Natl Acad Sci U.S.A doi: 10.1073/pnas.2023752118 – volume: 14 start-page: 13 year: 2023 ident: B9 article-title: CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies publication-title: Front Immunol doi: 10.3389/fimmu.2023.1101495 – volume: 19 start-page: 25 year: 2018 ident: B24 article-title: Schisandra chinensis fructus and its active ingredients as promising resources for the treatment of neurological diseases publication-title: Int J Mol Sci doi: 10.3390/ijms19071970 – volume: 17 year: 2020 ident: B2 article-title: The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications publication-title: Cell Mol Immunol doi: 10.1038/s41423-020-0488-6 – volume: 462 start-page: 23 year: 2019 ident: B4 article-title: Adoptive CD8+ T cell therapy against cancer:Challenges and opportunities publication-title: Cancer Lett doi: 10.1016/j.canlet.2019.07.017 |
SSID | ssj0000493335 |
Score | 2.3970428 |
Snippet | Following the approval of Chimeric Antigen Receptor T-cell Immunotherapy(CAR-T) in multiple countries, the Food and Drug Administration (FDA) approved... IntroductionFollowing the approval of Chimeric Antigen Receptor T-cell Immunotherapy(CAR-T) in multiple countries, the Food and Drug Administration (FDA)... |
SourceID | doaj pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 1537398 |
SubjectTerms | adoptive cell therapy Apoptosis - drug effects Biological Products - pharmacology Chinese medicine Coculture Techniques enhance immunity Hot Temperature Humans Immunology Immunotherapy, Adoptive - methods Jurkat Cells K562 Cells Neoplasms - immunology Neoplasms - therapy proteomics T-Lymphocytes - drug effects T-Lymphocytes - immunology T-Lymphocytes - metabolism temperature untargeted metabolomics |
Title | Screening and mechanistic study of natural compounds that enhance T cell anti-tumor effects post-heat treatment |
URI | https://www.ncbi.nlm.nih.gov/pubmed/40213558 https://www.proquest.com/docview/3188820098 https://pubmed.ncbi.nlm.nih.gov/PMC11983556 https://doaj.org/article/2aae19b576e744e9a55a0b66f4c1c5ec |
Volume | 16 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQJSQuiJZXoEWuxA2FxvEj8REQpeqBC620N8uPsXaRNqm62QP_npkkXe0iJC5ccsjTmW_smYm-fMPY--TbZKxRpcoJsEAJusSoCGUjKXmAJgCMbIvv5upWXS_0Yq_VF3HCJnngyXAXtfcgbMC0GBqlwHqtfRWMySqKqCHS6osxb6-Y-jnlvVJKPf0lg1WYvcir9XqL9WCtP-Ikb6RtDyLRKNj_tyzzT7LkXvS5fMaezmkj_zQN95g9gu6EPZ4aSf56zvofkfgzGIa47xJfA_3PO0ow81E_lveZjxKeeA8ikVMvpQ0fln7g0C0JeH7D6Rs-Xj6symG77u_5TPXgd_1mKGnN5jtW-gt2e_n15stVObdSKKOq66FMOtcxZQOSulOJHGIUHqdya_HFKhMbAUJ75aOqYpJKZxtJiK1OaPw2SSNfsqOu7-A147aOEpK3AVqrsgm-yl7IWKkm-NRkW7APD2Z1d5NihsNKg0BwIwiOQHAzCAX7TJbfnUlq1-MO9AE3-4D7lw8U7PwBN4ezg8zlO-i3G4crFpYQJJpasFcTjrtHYeUsSFy-YO0BwgdjOTzSrZajArcQFq2jzZv_Mfq37AlZhIhtdXPKjob7LZxhpjOEd6NT4_bbQvwGsPwB9Q |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Screening+and+mechanistic+study+of+natural+compounds+that+enhance+T+cell+anti-tumor+effects+post-heat+treatment&rft.jtitle=Frontiers+in+immunology&rft.au=Wang%2C+Zhaoyi&rft.au=Diao%2C+Zhongqi&rft.au=Zhang%2C+Yiyan&rft.au=Liu%2C+Jiangying&rft.date=2025-03-27&rft.pub=Frontiers+Media+S.A&rft.eissn=1664-3224&rft.volume=16&rft_id=info:doi/10.3389%2Ffimmu.2025.1537398&rft.externalDocID=PMC11983556 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon |